Citations 3
Do Early Relapses Predict the Risk of Long‐Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD ?
Chen, Bo , Gómez‐Figueroa, Enrique , Redenbaugh, Vyanka , Satukijchai, Chanjira , Messina, Silvia , Sá, Mário , Woodhall, Mark , Paul, Friedemann , Robertson, Neil P. , Lim, Ming , Wassmer, Evangeline , Kneen, Rachel , Huda, Saif , Blain, Camilla, Halfpenny, Christopher , O’Sullivan, Eoin , Hobart, Jeremy , Fisniku, Leonora , Martin, Roswell , Cooper, Sarah , Williams, Victoria , Chen, John J. , Pittock, Sean J. , Ramdas, Sithara , Leite, Maria Isabel , Geraldes, Ruth , Palace, Jacqueline , Pittock, S J , Messina, Silvia , Sa, Mario , Lim, Ming , Dobson, Ruth , Chen, John J , Paul, Friedemann , Geraldes, Ruth , Palace, Jacqueline , Wassmer, Evangeline , Francis, Anna G. , Wu, Yan Ting , Hemingway, Cheryl , Williams, Victoria, Waters, Patrick , Flanagan, Eoin P.
Annals of Neurology | July 3, 2023 | Volume: 94 | Issue: 3 | Pages: 508-517
Objective Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) can be monophasic or relapsing, with early relapse being a feature. However, the relevance of early relapse on longer‐term relapse risk is unknown. Here, we investigate whether early relapses increase longer‐term relapse risk in patients with MOGAD. Methods A retrospective analysis of 289 adult‐ and pediatric‐onset patients with MOGAD followed for at least 2 years in 6 specialized referral centers. “Early relapses” were defined as attacks within the first 12 months from onset, with “very early relapses” defined within 30 to 90 days from onset and “delayed early relapses” defined within 90 to 365 days. “Long‐term relapses” were defined as relapses beyond 12 months. Cox regression modeling and Kaplan–Meier survival analysis were used to estimate the long‐term relapse risk and rate. Results Sixty‐seven patients (23.2%) had early relapses with a median number of 1 event. Univariate analysis revealed an elevated risk for long‐term relapses if any “early relapses” were present (hazard ratio [HR] = 2.11, p < 0.001), whether occurring during the first 3 months (HR = 2.70, p < 0.001) or the remaining 9 months (HR = 1.88, p = 0.001), with similar results yielded in the multivariate analysis. In children with onset below aged 12 years, only delayed early relapses were associated with an increased risk of long‐term relapses (HR = 2.64, p = 0.026). Interpretation The presence of very early relapses and delayed early relapses within 12 months of onset in patients with MOGAD increases the risk of long‐term relapsing disease, whereas a relapse within 90 days appears not to indicate a chronic inflammatory process in young pediatric‐onset disease. ANN NEUROL 2023;94:508–517
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Tur, Carmen , Otero‐Romero, Susana , Amato, Maria Pia , Derfuss, Tobias , Pauli, Franziska Di , Abboud, Hesham , Achiron, Anat , Casanova, Jean‐Laurent , Clifford, David B. , Fonderico, Mattia , Gouider, Riadh , Hacohen, Yael , Kappos, Ludwig , Ladeira, Filipa , Louapre, Céline , Magyari, Melinda , Papeix, Caroline , Piehl, Fredrik , Ruíz-Camps, Isabel , Selmaj, Krzysztof , Simpson, Steve , Sıva, Aksel , Vaknin‐Dembinsky, Adi , Weinshenker, Brian G. , Winkelmann, Alexander, Rodas, María Isabel Zuluaga , Tintoré, Mar , Amato, Maria Pia , Derfuss, Tobias , Abboud, Hesham , Achiron, Anat , Dobson, Ruth , Filippi, Massimo , Fitzgerald, Kathryn C , Fonderico, Mattia , Hellwig, Kerstin , Hemmer, Bernhard , Ladeira, Filipa , Lebrun‐Frénay, Christine , Magyari, Melinda , Oreja-Guevara, Celia , Pandit, Lekha , Papeix, Caroline , Portaccio, Emilio , Simpson-Yap, Steve , Siva, Aksel , Sormani, Maria P , Vukusic, Sandra , Wiendl, Heinz , Tintoré, Mar , Weinshenker, Brian G , Casanova, Jean Laurent , Hacohen, Yael , Dubessy, Anne‐Laure , Iacobaeus, Ellen , Mycko, Marcin P. , Bellinvia, Angelo , Boyко, Alexey , Farez, Mauricio , Filippi, Massimo , Mehling, Matthias , Oreja‐Guevara, Celia , Pandit, Lekha , Sørensen, Per Soelberg , Sormani, Maria Pia , Trojano, María , Wiendl, Heinz , Stankoff, Bruno
Multiple Sclerosis Journal | February 24, 2022 | Volume: 28 | Issue: 9 | Pages: 1424-1456
Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
Sex effects across the lifespan in women with multiple sclerosis
Krysko, Kristen M. , Bernard, Jacqueline , Bonavita, Simona , Bove, Riley , Clerico, Marinella , Corona, Teresa , Doshi, Anisha , Jacobs, Dina , Landi, Doriana , Llamosa, Gloria , Longbrake, Erin E. , Marta, Mónica , Shah, Suma , Walt, Anneke van der , Voskuhl, Rhonda R. , Wang, Yujie , Zabad, Rana , Zeydan, Burcu , Houtchens, Maria K. , van der Walt, Anneke , Hellwig, Kerstin , Zeydan, Burcu , Longbrake, Erin E , Krysko, Kristen M , Graves, Jennifer , Dobson, Ruth , Altıntaş, Ayşe , Amato, Maria Pia , Cavalla, Paola , Fragoso, Yára Dadalti , Jokubaitis, Vilija , Maillart, Elisabeth , Midaglia, Luciana Soledad , Tintoré, Mar
Therapeutic Advances in Neurological Disorders | July 1, 2020 | Volume: 13 | Issue: No issue available | Pages: No page available
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating central nervous system disorder that is more common in women, with onset often during reproductive years. The female:male sex ratio of MS rose in several regions over the last century, suggesting a possible sex by environmental interaction increasing MS risk in women. Since many with MS are in their childbearing years, family planning, including contraceptive and disease-modifying therapy (DMT) counselling, are important aspects of MS care in women. While some DMTs are likely harmful to the developing fetus, others can be used shortly before or until pregnancy is confirmed. Overall, pregnancy decreases risk of MS relapses, whereas relapse risk may increase postpartum, although pregnancy does not appear to be harmful for long-term prognosis of MS. However, ovarian aging may contribute to disability progression in women with MS. Here, we review sex effects across the lifespan in women with MS, including the effect of sex on MS susceptibility, effects of pregnancy on MS disease activity, and management strategies around pregnancy, including risks associated with DMT use before and during pregnancy, and while breastfeeding. We also review reproductive aging and sexual dysfunction in women with MS.